Gilead Sciences Beats Revenue Estimates With Strong HIV Sales

Gilead Sciences reported second-quarter revenue of $7.8 billion, marking a 10% increase that surpassed the $7.4 billion estimate projected by Wall Street. This growth was largely fueled by a 12% rise in HIV product sales, including Biktarvy, Descovy, and the new injection Yeztugo, alongside gains from the liver disease drug Livdelzi and cancer drug Trodelvy.

Despite the revenue beat, the company posted a quarterly net loss of $8.45 per share. This loss resulted primarily from charges associated with the acquisitions of Arcellx, Ouro Medicines, and Tubulis. Following these results, the company slightly increased its full-year 2026 revenue outlook to a range between $30.1 billion and $30.4 billion and narrowed its projected adjusted loss to between 65 cents and 30 cents per share.

In a separate legal development, the highest court in California dismissed negligence claims against the company concerning the discontinuation of an HIV drug developed more than 20 years ago.